<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613261</url>
  </required_header>
  <id_info>
    <org_study_id>C20002</org_study_id>
    <secondary_id>2012-000831-22</secondary_id>
    <nct_id>NCT01613261</nct_id>
  </id_info>
  <brief_title>Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies</brief_title>
  <official_title>A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multicenter, Open-label, Phase 1b Study of TAK-733 in Combination With Alisertib in
      Adult Patients With Advanced Nonhematologic Malignancies
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs), Serious Adverse Events (SAEs), assessments of clinical laboratory values, and vital sign measurements</measure>
    <time_frame>From signing of the informed consent form through 30 days after the last dose of study drug</time_frame>
    <description>To evaluate the safety profile and to determine DLTs, MTDs, and RP2D of oral TAK-733 + alisertib in patients with advanced nonhematologic malignancies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TAK-733 and alisertib PK parameters including, but not limited to Cmax, Tmax, Area Under Curve (AUC), apparent oral clearance (CL/F), peak-to-trough ratio, and accumulation ratio</measure>
    <time_frame>Escalation and MTD Refinement: Cycle 1-Day 1, 2, 7, 8, 14,and 15; Tumor Expansion Cohort: Cycle 1-Day 1, 7, 8, and 15; Cycle 2-Day 1, 8,and 15; PK Expansion Cohort: Cycle 1-Day 1, 7, and 8; Cycle 2-Day 7, 14, and 15. Each cycle is a 21 days cycle</time_frame>
    <description>To characterize the single- and multiple-dose plasma PK of TAK-733 and alisertib in patients with advanced nonhematologic malignancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures of disease response, including objective response rate and duration of response based on investigator's assessment using RECIST guidelines</measure>
    <time_frame>On screening; Cycle 2: between Day 15 and 21, and every third cycle thereafter (5,8,11 etc.) until progressive disease for approximately 1 year</time_frame>
    <description>To evaluate evidence of antitumor activity of TAK-733 + alisertib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Advanced Nonhematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>TAK-733 and alisertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-733 and alisertib</intervention_name>
    <description>TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.
Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle.</description>
    <arm_group_label>TAK-733 and alisertib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years or older

          -  Patients must have a diagnosis of a solid tumor malignancy for which standard,
             curative, or life-prolonging treatment does not exist or is no longer effective

          -  Radiographically or clinically evaluable tumor

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

          -  Female patients who are post menopausal for at least 1 year, surgically sterile, or
             agree to practice 2 effective methods of contraception through 30 days after the last
             dose of study drug or agree to abstain from heterosexual intercourse

          -  Male patients who agree to practice effective barrier contraception through 4 months
             after the last dose of alisertib or agree to abstain from heterosexual intercourse

          -  Voluntary written consent

          -  Clinical laboratory values as specified in the protocol

        Exclusion Criteria:

          -  Female patients who are breastfeeding and lactating or pregnant

          -  Serious medical or psychiatric illness or laboratory abnormality that could, in the
             investigator's opinion, potentially interfere with the completion of treatment
             according to the protocol

          -  Treatment with any investigational products within 28 days before the first dose of
             study drug

          -  Prior treatment with Aurora A-targeted agents, including alisertib

          -  Prior treatment with MEK inhibitors, including TAK-733

          -  Prior treatment with BRAF inhibitors

          -  Systemic anticancer therapy within 21 days before the first dose

          -  Prior biologic or immunotherapy within 28 days before the first dose

          -  Major surgery or serious infection within 14 days before the first dose

          -  Life-threatening illness unrelated to cancer

          -  Known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or
             hepatitis C

          -  Cardiac condition as specified in study protocol or severe CNS, pulmonary, renal or
             hepatic disease

          -  Known GI conditions or GI procedure that could interfere with the oral absorption or
             tolerance of study drugs

          -  History of uncontrolled sleep apnea syndrome or other conditions that could result in
             excessive daytime sleepiness

          -  History of ongoing or a newly diagnosed eye abnormality

          -  Symptomatic brain metastases

        Please note that there are additional inclusion and exclusion criteria. The study center
        will determine if you meet all of the criteria.

        Site personnel will explain the trial in detail and answer any question you may have if you
        do qualify for the study. You can then decide whether or not you wish to participate. If
        you do not qualify for the trial, site personnel will explain the reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics (START)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAK-733,</keyword>
  <keyword>alisertib,</keyword>
  <keyword>MLN8237,</keyword>
  <keyword>Oral MEK Inhibitor,</keyword>
  <keyword>Oral Aurora A Kinase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

